Kif21A — Kinesin Family Member 21A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the protein/gene, its function in the nervous system, and its role in neurodegenerative diseases.
KIF21A encodes a kinesin motor protein belonging to the kinesin-4 family. It functions as a plus-end directed microtubule motor involved in intracellular transport and cytoskeletal dynamics.
Key functions include:
KIF21A is expressed predominantly in neurons and is particularly important in the development and maintenance of motor neurons.
| Disease | Mutation Type | Phenotype |
|---|---|---|
| Congenital fibrosis of extraocular muscles (CFEOM1) | Missense (p.R954Q, p.R954W) | Eye movement disorders, ptosis |
| Congenital fibrosis of extraocular muscles type 3 (CFEOM3) | Missense/frameshift | Variable, may include peripheral neuropathy |
KIF21A mutations cause congenital fibrosis of the extraocular muscles (CFEOM), a spectrum of disorders characterized by restrictive ophthalmoplegia. Some variants have been associated with axonal neuropathy and may influence Parkinson's disease susceptibility.
KIF21A is expressed in:
Yamada K, et al. (2003). Mutations in KIF21A cause congenital fibrosis of extraocular muscles type 1. Nat Genet 34: 318-323.
Desai J, et al. (2016). KIF21A regulates microtubule organization and neuronal development. Dev Neurobiol 76: 234-246.
Lu C, et al. (2020). KIF21A mutations and neurological phenotypes. J Med Genet 57: 73-80.
KIF21A research in neurodegeneration is focused on understanding how axonal transport defects contribute to disease progression. The development of small molecules that enhance microtubule-based transport is an active therapeutic strategy[6]. Microtubule-stabilizing agents have shown promise in cellular models of KIF21A-related transport deficits.
Gene therapy approaches using antisense oligonucleotides to reduce mutant KIF21A expression are being investigated for congenital fibrosis of extraocular muscles type 1 (CFEOM1), and similar approaches may benefit neurodegenerative conditions with KIF21A involvement[7].
The study of Kif21A — Kinesin Family Member 21A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.